EGFR and neoplasm: Disruption of the EGFR signalling system, both by antagonistic effects on EGFR binding sites, particularly on the extracellular domain of the receptor or by inactivating intracellular tyrosine kinase, can potentially control (inhibit) the growth EGFR-mediated tumours and show some improvement in the patient's condition.